Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults

Korsgaard, J.; Frimodt‐Møller, Niels; Kilian, Mogens

doi:10.1016/j.ijid.2004.07.013

Cited by 24 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present authors have previously demonstrated that the present urinary antigen test is more often positive in those pre-treated than in those not pre-treated with antibiotics [14]. Thus, mPCR and the urinary antigen test appear useful in patients treated with antibiotics, in order to identify S. pneumoniae in patients who will probably give false negative results in their cultures.…”

Section: Discussionmentioning

confidence: 51%

“…Silkeborg County Hospital is the only hospital in the region and serves a basic population of 100,000 inhabitants in the area. As previously described [14], all immunocompetent adult patients hospitalised for LRTI during weekdays between September 1997 and August 2000 were consecutively included in the present study. Thus, the included patients were unselected adult patients with LRTI requiring hospitalisation.…”

Section: Study Subjectsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a multiplex PCR for bacterial pathogens applied to bronchoalveolar lavage

Strålin

Korsgaard²,

Olcén³

2006

Eur Respir J

View full text Add to dashboard Cite

The present study assessed the diagnostic usefulness of a multiplex PCR (mPCR) for Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae and Chlamydophila pneumoniae applied to bronchoalveolar lavage (BAL).Fibreoptic bronchoscopy was performed on 156 hospitalised adult patients with lower respiratory tract infection (LRTI) and 36 controls. BAL fluid was analysed with bacterial culture and mPCR.By conventional diagnostic methods, S. pneumoniae, H. influenzae, M. pneumoniae and C. pneumoniae were aetiological agents in 14, 21, 3.2 and 0% of the LRTI patients, respectively. These pathogens were identified by BAL mPCR in 28, 47, 3.2 and 0.6% of cases, respectively, yielding sensitivities of 86% for S. pneumoniae, 88% for H. influenzae, 100% for M. pneumoniae and 0% for C. pneumoniae, and specificities of 81, 64, 100 and 99% for S. pneumoniae, H. influenzae, M. pneumoniae and C. pneumoniae, respectively. Of the 103 patients who had taken antibiotics prior to bronchoscopy, S. pneumoniae was identified by culture in 2.9% and by mPCR in 31%. Among the controls, mPCR identified S. pneumoniae in 11% and H. influenzae in 39%.In lower respiratory tract infection patients, bronchoalveolar lavage multiplex PCR can be useful for identification of Streptococcus pneumoniae, Mycoplasma pneumoniae and Chlamydophila pneumoniae. The method appears to be particularly useful in patients treated with antibiotics.

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Study Subjectsmentioning

confidence: 99%

Evaluation of a multiplex PCR for bacterial pathogens applied to bronchoalveolar lavage

Strålin

Korsgaard²,

Olcén³

2006

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…There are many pneumonia treatments available, such as antibiotics, breathing treatments, and oxygen therapy (Korsgaard et al 2005; van der Poll and Opal 2009). However, people with weak immune systems are likely to have complications such as respiratory failure, uncontrolled inflammation (i.e., sepsis), and lung abscesses (CDC 2017).…”

Section: Pneumoniamentioning

confidence: 99%

Pneumonia and Streptococcus pneumoniae vaccine

2017

View full text Add to dashboard Cite

Pneumonia is an inflammatory disease of the lung, responsible for high morbidity and mortality worldwide. It is caused by bacteria, viruses, fungi, or other microorganisms. Streptococcus pneumoniae, a gram-positive bacterium with over 90 serotypes, is the most common causative agent. Moreover, comorbid factors including heart failure, renal disease, and pulmonary disease could increase the risk of pneumococcal pneumonia. Since the advent of the pneumococcal vaccine in the 1980s, the incidence of pneumonia has decreased significantly. However, current vaccines confer only limited protection against serotypes included in the vaccine. Thus, to overcome this limitation, new types of pneumococcal vaccines have been sought and under clinical trials. In this review, we discuss pneumonia and summarize the various types of pneumococcal vaccines in progress.

show abstract

“…L. pneumophila serogroup 1 antigen detection in urine is the most rapid method to diagnose or exclude the infection. A negative test makes legionella unlikely, but does not exclude legionella infection’ [A3] [209,214–242].…”

mentioning

confidence: 99%

Guidelines for the management of adult lower respiratory tract infections - Summary

Woodhead

Blasi

Ewig

et al. 2011

Clinical Microbiology and Infection

307

118

View full text Add to dashboard Cite

This document is an update of Guidelines published in 2005 and now includes scientific publications through to May 2010. It provides evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI. Topics include management outside hospital, management inside hospital (including community-acquired pneumonia (CAP), acute exacerbations of COPD (AECOPD), acute exacerbations of bronchiectasis) and prevention. The target audience for the Guideline is thus all those whose routine practice includes the management of adult LRTI.

show abstract

Antibiotic treatment and the diagnosis of Streptococcus pneumoniae in lower respiratory tract infections in adults

Cited by 24 publications

References 18 publications

Evaluation of a multiplex PCR for bacterial pathogens applied to bronchoalveolar lavage

Evaluation of a multiplex PCR for bacterial pathogens applied to bronchoalveolar lavage

Pneumonia and Streptococcus pneumoniae vaccine

Guidelines for the management of adult lower respiratory tract infections - Summary

Contact Info

Product

Resources

About